{"id":53231,"date":"2026-01-07T20:57:01","date_gmt":"2026-01-07T12:57:01","guid":{"rendered":"https:\/\/flcube.com\/?p=53231"},"modified":"2026-01-07T20:57:02","modified_gmt":"2026-01-07T12:57:02","slug":"sanofis-tzield-wins-fda-priority-review-for-pediatric-t1d-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53231","title":{"rendered":"Sanofi&#8217;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion"},"content":{"rendered":"\n<p><strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted for <strong>priority review<\/strong> the supplemental biologic license application (sBLA) for <strong>Tzield (teplizumab\u2011mzwv)<\/strong> to expand the age indication from <strong>8 years and above to as young as 1 year old and above<\/strong> for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is <strong>April\u202f29, 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Tzield (teplizumab\u2011mzwv)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Sanofi (NASDAQ: SNY)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>sBLA accepted for FDA priority review<\/td><\/tr><tr><td><strong>Current Indication<\/strong><\/td><td>Delay stage\u202f3 T1D onset in adults\/children 8+ years with stage\u202f2 T1D (approved Nov\u202f2022)<\/td><\/tr><tr><td><strong>Proposed Expansion<\/strong><\/td><td>Lower age limit to <strong>1 year and above<\/strong><\/td><\/tr><tr><td><strong>FDA Target Action Date<\/strong><\/td><td>April\u202f29, 2026<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CD3\u2011directed monoclonal antibody<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First and only disease\u2011modifying therapy for autoimmune T1D<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-basis-petite-t1d-study\">Clinical Basis: PETITE\u2011T1D Study<\/h2>\n\n\n\n<p><strong>Study Design<\/strong>: Ongoing <strong>Phase\u202f4 PETITE\u2011T1D trial (NCT05757713)<\/strong> evaluating safety and pharmacokinetics of Tzield in <strong>young children (1\u20117 years)<\/strong>.<\/p>\n\n\n\n<p><strong>Interim One\u2011Year Data<\/strong>: Positive results supported the sBLA filing, demonstrating <strong>comparable safety profile<\/strong> to older children and <strong>no unexpected toxicities<\/strong>. <strong>Efficacy signals<\/strong> consistent with adult\/pediatric data from original approval (TN\u201110 study).<\/p>\n\n\n\n<p><strong>Market Validation<\/strong>: Expanding to <strong>toddlers<\/strong> addresses <strong>critical unmet need<\/strong> as <strong>T1D incidence peaks at ages 5\u20117<\/strong>, creating a <strong>3\u2011year broader treatment window<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-pediatric-t1d\">Market Opportunity: Pediatric T1D<\/h2>\n\n\n\n<p><strong>U.S. Epidemiology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Annual Incidence<\/strong>: <strong>1 in 300 children<\/strong> develop T1D by age\u202f18<\/li>\n\n\n\n<li><strong>Stage\u202f2 Population<\/strong>: <strong>~15,000\u201120,000<\/strong> children aged 1\u20117 at risk annually<\/li>\n\n\n\n<li><strong>Diagnosis Gap<\/strong>: <strong>&lt;10%<\/strong> of at\u2011risk children screened; <strong>massive expansion potential<\/strong> with newborn screening programs<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. T1D Prevention Market<\/strong>: <strong>$500\u2011700\u202fmillion<\/strong> peak potential by 2030<\/li>\n\n\n\n<li><strong>Global Market<\/strong>: <strong>$1.2\u20111.5\u202fbillion<\/strong> (including EU, Japan)<\/li>\n\n\n\n<li><strong>Sanofi\u2019s Share<\/strong>: <strong>70\u201180%<\/strong> if approved, given <strong>first\u2011mover advantage<\/strong> and <strong>12\u2011year regulatory exclusivity<\/strong> (orphan drug + pediatric extension)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Target Population<\/th><\/tr><\/thead><tbody><tr><td><strong>Tzield<\/strong><\/td><td><strong>Sanofi<\/strong><\/td><td>CD3 monoclonal antibody<\/td><td><strong>sBLA under review<\/strong><\/td><td>Stage\u202f2 T1D (1\u201145\u202fyrs proposed)<\/td><\/tr><tr><td><strong>Teplizumab<\/strong><\/td><td>Provention Bio (acquired by Sanofi)<\/td><td>Same as above<\/td><td>Marketed (8+\u202fyrs)<\/td><td>Stage\u202f2 T1D (8\u201145\u202fyrs)<\/td><\/tr><tr><td><strong>DF\u2011006<\/strong><\/td><td>Diamyd Medical<\/td><td>GABA receptor modulator<\/td><td>Phase\u202fII<\/td><td>New\u2011onset T1D<\/td><\/tr><tr><td><strong>Ladarixin<\/strong><\/td><td>Lilly\/Prevail<\/td><td>CXCR1\/2 inhibitor<\/td><td>Phase\u202fII<\/td><td>New\u2011onset T1D<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Moat<\/strong>: Tzield\u2019s <strong>12\u2011year exclusivity<\/strong> (orphan drug + pediatric voucher) creates <strong>near\u2011monopoly<\/strong> in T1D delay indication until <strong>2038\u20112040<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-implications\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<p><strong>Revenue Impact<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Sales<\/strong>: <strong>$90\u202fmillion<\/strong> (2025, U.S. only, limited by age restriction)<\/li>\n\n\n\n<li><strong>Post\u2011Expansion Projection<\/strong>: <strong>$450\u2011600\u202fmillion<\/strong> (U.S.) by 2028; <strong>$1.2\u202fbillion<\/strong> globally with EU\/Japan approvals<\/li>\n<\/ul>\n\n\n\n<p><strong>Pricing<\/strong>: <strong>$13,850 per 14\u2011day course<\/strong> (unchanged); <strong>no price reduction<\/strong> needed given <strong>lack of competition<\/strong> and <strong>high value<\/strong> (delaying insulin dependence by <strong>\u22652\u202fyears<\/strong>).<\/p>\n\n\n\n<p><strong>Sanofi\u2019s Immunology Strategy<\/strong>: Strengthens portfolio alongside <strong>Dupixent<\/strong> (IL\u20114\/13) and <strong>Kevzara<\/strong> (IL\u20116), creating <strong>comprehensive autoimmune franchise<\/strong> with <strong>lifecycle management<\/strong> potential.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FDA approval probability, pediatric market penetration, revenue forecasts, and competitive positioning for Tzield. Actual results may differ materially due to regulatory review outcomes, pediatric adoption rates, and potential competitive entrants.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,38,867,80,147],"class_list":["post-53231","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-diabetes","tag-market-approval-filings","tag-nasdaq-sny","tag-priority-reviews","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi&#039;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab\u2011mzwv) to expand the age indication from 8 years and above to as young as 1 year old and above for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is April\u202f29, 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53231\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi&#039;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab\u2011mzwv) to expand the age indication from 8 years and above to as young as 1 year old and above for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is April\u202f29, 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53231\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T12:57:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T12:57:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53231#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53231\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi&#8217;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion\",\"datePublished\":\"2026-01-07T12:57:01+00:00\",\"dateModified\":\"2026-01-07T12:57:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53231\"},\"wordCount\":498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"Market approval filings\",\"NASDAQ: SNY\",\"Priority reviews\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53231#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53231\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53231\",\"name\":\"Sanofi's Tzield Wins FDA Priority Review for Pediatric T1D Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T12:57:01+00:00\",\"dateModified\":\"2026-01-07T12:57:02+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab\u2011mzwv) to expand the age indication from 8 years and above to as young as 1 year old and above for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is April\u202f29, 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53231#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53231\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53231#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi&#8217;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Tzield Wins FDA Priority Review for Pediatric T1D Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab\u2011mzwv) to expand the age indication from 8 years and above to as young as 1 year old and above for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is April\u202f29, 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53231","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Tzield Wins FDA Priority Review for Pediatric T1D Expansion","og_description":"Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab\u2011mzwv) to expand the age indication from 8 years and above to as young as 1 year old and above for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is April\u202f29, 2026.","og_url":"https:\/\/flcube.com\/?p=53231","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T12:57:01+00:00","article_modified_time":"2026-01-07T12:57:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53231#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53231"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi&#8217;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion","datePublished":"2026-01-07T12:57:01+00:00","dateModified":"2026-01-07T12:57:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53231"},"wordCount":498,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","Market approval filings","NASDAQ: SNY","Priority reviews","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53231#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53231","url":"https:\/\/flcube.com\/?p=53231","name":"Sanofi's Tzield Wins FDA Priority Review for Pediatric T1D Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T12:57:01+00:00","dateModified":"2026-01-07T12:57:02+00:00","description":"Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab\u2011mzwv) to expand the age indication from 8 years and above to as young as 1 year old and above for delaying the onset of stage\u202f3 type\u202f1 diabetes (T1D) in patients diagnosed with stage\u202f2 T1D. The target action date for the FDA decision is April\u202f29, 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53231#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53231"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53231#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi&#8217;s Tzield Wins FDA Priority Review for Pediatric T1D Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53231"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53231\/revisions"}],"predecessor-version":[{"id":53233,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53231\/revisions\/53233"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}